Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BISCUIT: Remibrutinib for Chronic Spontaneous Urticaria in Japanese Patients
NCT05048342Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of remibrutinib in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Jan 2022; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05048342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048342.